DrugPatentWatch Database Preview
B - Biologic Drug Details
Company Disclosures: US Patents for b
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Athena Neurosciences, Inc. (South San Francisco, CA) | 2014-01-25 | RX | Orphan | company |
Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Biogen, Inc. (Cambridge, MA) | 2020-08-05 | RX | Orphan | company |
Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | Athena Neurosciences, Inc. (South San Francisco, CA) | 2014-01-25 | RX | Orphan | company |
Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | Biogen, Inc. (Cambridge, MA) | 2020-08-05 | RX | Orphan | company |
Amgen | BLINCYTO | blinatumomab | INJECTABLE;INJECTION | 125557 | 001 | 2014-12-03 | Start Trial | Micromet AG (Munich, DE) | 2018-04-21 | RX | Orphan | company |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for b
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Seattle Genetics | ADCETRIS | brentuximab vedotin | INJECTABLE; INJECTION | 125388 | 001 | 2011-08-19 | Start Trial | University of Georgia Research Foundation, Inc. (Athens, GA) | 2039-02-26 | RX | Orphan | search |
Seattle Genetics | ADCETRIS | brentuximab vedotin | INJECTABLE; INJECTION | 125388 | 001 | 2011-08-19 | Start Trial | SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) | 2034-07-17 | RX | Orphan | search |
Seattle Genetics | ADCETRIS | brentuximab vedotin | INJECTABLE; INJECTION | 125388 | 001 | 2011-08-19 | Start Trial | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | Orphan | search |
Seattle Genetics | ADCETRIS | brentuximab vedotin | INJECTABLE; INJECTION | 125388 | 001 | 2011-08-19 | Start Trial | Celgene Corporation (Summit, NJ) | 2035-12-02 | RX | Orphan | search |
Seattle Genetics | ADCETRIS | brentuximab vedotin | INJECTABLE; INJECTION | 125388 | 001 | 2011-08-19 | Start Trial | SEATTLE GENETICS, INC. (Bothell, WA) | 2030-10-22 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |